Recombinant Human Brachyury protein (T)

Code CSB-YP023052HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP023052HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP023052HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP023052HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP023052HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
T
Uniprot No.
Alternative Names
BRAC_HUMAN; Brachyury homolog; Brachyury protein; Bry; MGC104817; Protein T; SAVA; T; T brachyury homolog; T brachyury transcription factor; T Protein; T, brachyury homolog (mouse); TFT; Transcription factor T
Species
Homo sapiens (Human)
Expression Region
1-435
Target Protein Sequence
MSSPGTESAG KSLQYRVDHL LSAVENELQA GSEKGDPTER ELRVGLEESE LWLRFKELTN EMIVTKNGRR MFPVLKVNVS GLDPNAMYSF LLDFVAADNH RWKYVNGEWV PGGKPEPQAP SCVYIHPDSP NFGAHWMKAP VSFSKVKLTN KLNGGGQIML NSLHKYEPRI HIVRVGGPQR MITSHCFPET QFIAVTAYQN EEITALKIKY NPFAKAFLDA KERSDHKEMM EEPGDSQQPG YSQWGWLLPG TSTLCPPANP HPQFGGALSL PSTHSCDRYP TLRSHRSSPY PSPYAHRNNS PTYSDNSPAC LSMLQSHDNW SSLGMPAHPS MLPVSHNASP PTSSSQYPSL WSVSNGAVTP GSQAAAVSNG LGAQFFRGSP AHYTPLTHPV SAPSSSGSPL YEGAAAATDI VDSQYDAAAQ GRLIASWTPV SPPSM
Protein Length
Full length protein
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

 Q&A
Q:

The specific vaccine requested for manufacture is a yeast-based recombinant vaccine targeting the Brachyury transcription factor (GI-6301), in line with the methods detailed by (Heery et al., 2015, Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research, 3, 1248-1256) for experimental purposes.
The yeast-brachyury (GI-6301) recombinant vaccine is composed of heat-killed recombinant S. cerevisiae overexpressing the human brachyury protein. The composition of the vaccine (i.e. antigen), formulation and methodology for production of the vaccine in a yeast expression system is detailed in the patent (please refer to patent no. US0106824A1 (2016) and US9623097B2 (2017)). In summary, yeast cells were transformed with a recombinant nucleic acid molecule encoding the Brachyury antigen under the control of a CUP1 promoter. Antigen expression was induced in yeast cells with CuSO4 in a suitable medium where the pH was maintained at pH 5.5 or higher (6-8 hour culture period). Post-harvest of cultures, yeast cells were heat-inactivated at 56° C for 1 hour. Subsequently, the yeast cells were formulated for injection with a pharmaceutically acceptable excipient. The manufacture of the vaccine is requested for research purposes. The vaccine will not be marketed and distributed to third parties on a commercial basis. The intended use falls into Hatch-Waxman Act in the United States for patented use of drugs for experimental purpose.
Enquiry:
1. Can you manufacture the yeast-based recombinant vaccine?
2. Would it be possible to manufacture under GMP conditions?
3. What would be the purity level achieved during the manufacture process?

A:
Thanks for your inquiry.
1. Our product is for research use only, can't be used in clinical diagnostic. For the research purposes vaccine it's ok. The production method is not the same as you mentioned. The yeast we use is Pichia pastoris, AOX1 promoter, methanol induced expressio.
2. Our proteins are not GMP certificate. We have the standard SOP preparation process. Cooperate a lot with the pharmaceutical companies in the world wide.
3. The purity of our protein is over 85% ( SDS-PAGE), If you have other purity request, we could try our best to meet it.

Target Background

Function
Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence and activates gene transcription when bound to such a site.
Gene References into Functions
  1. Brachyury expression in tumor samples is not a sensitive indicator of prognosis in chordomas PMID: 28094431
  2. Notochordal transcription factor Brachyury gene duplication in sporadic chordoma PMID: 29026114
  3. FGFR1/MAPK may be important for brachyury activation in lung cancer, and this pathway may be an appealing therapeutic target for a subset of brachyury-driven lung cancer. PMID: 27893433
  4. our results indicate that Brachyury contributes to tumor chemotherapy resistance, constituting an attractive target for advanced prostate cancer patients PMID: 27049720
  5. A strong association was observed between nuclear brachyury protein expression and the stage of disease, with nuclear brachyury being more predominant in metastatic vs primary tumors. PMID: 27580659
  6. rs2305089 variant in T (brachyury) gene is associated with response to therapy in Spinal column chordoma. PMID: 27663388
  7. Brachyury was significantly associated with estrogen receptor positive and human epidermal growth factor receptor 2 negative status; further study would be needed to clarify how it affects treatment prognosis. PMID: 28621227
  8. Brachyury is a candidate marker for predicting the clinical efficacy of tamoxifen. PMID: 27621036
  9. Overexpression of Brachyury in the cytoplasm is predictive of poor prognosis in gastrointestinal stromal tumors. PMID: 25995035
  10. Results showed that the high expression of SMC1 often promoted epithelial-mesenchymal transition, accompanied by the enhanced expression of Brachyury in triple-negative breast cancer cells. PMID: 26781859
  11. The distinct expression patterns of T gene isoforms may contribute to the pathogenesis of skull base chordomas. PMID: 26435504
  12. Brachyury expression promotes lung cancer cell proliferation and invasion, and correlates with reduced patient survival. PMID: 25683840
  13. Nuclear brachyury expression is prevalent in embryonal carcinoma, seminoma, and small cell carcinoma of the lung but very rare in common carcinomas, sarcomas, and melanoma. PMID: 26099010
  14. Elevated Brachyury facilitates hepatocellular carcinoma metastasis by promoting EMT via PTEN/Akt/Snail-dependent pathway. PMID: 25499255
  15. we found that Brachyury expression was inversely correlated with CCL2 and CCL4 expression in human lung tumors PMID: 25744730
  16. Brachyury plays an important role in regulating TGF beta 1-mediated renal epithelial mesenchymal transition and could be an attractive target for progression of renal disease therapies PMID: 25433496
  17. The data illuminate the function of BRA in the context of human embryonic development and show that the regulatory role of BRA is context dependent. PMID: 26015544
  18. the present study suggests that Brachyury plays an important role in prostate cancer aggressiveness and points, for the first time, to Brachyury as a significant predictor of poor prostate cancer prognosis PMID: 25009296
  19. Brachyury separates chordoma from cytomorphologic mimics with high sensitivity and specificity in small biopsies. PMID: 24554551
  20. Brachyury expression may useful for the differential diagnosis of renal hemangioblastoma from other neoplastic histological mimickers. [Review] PMID: 24591762
  21. Brachyury knockdown reduces invasiveness and chemoresistance and radioresistance of cancer stem cells in vivo. PMID: 24504414
  22. Importance of the T gene in the pathogenesis of both familial and sporadic chordoma. PMID: 24990759
  23. Activated brachury is associated with chordoma. PMID: 24445144
  24. The level of brachyury expression in breast cancer cells was positively associated with their ability to invade the extracellular matrix, efficiently form mammospheres in vitro, and resist the cytotoxic effect of docetaxel PMID: 24815864
  25. Multiple abnormalities, consisting of sacral agenesis, abnormal ossification of the vertebral bodies and a persistent notochordal canal, are associated with mutations in the T (brachyury) gene. PMID: 24253444
  26. High expression of Brachyury gene is associated with lung carcinoma. PMID: 23456319
  27. We report two cases of recurrent EAC confirmed by the expression of brachyury arising from the distal femur and distal tibia and describe the imaging findings from radiography and MRI at initial diagnosis and at recurrence. PMID: 23653219
  28. Common variants of PAX3 and T are associated with spina bifida. PMID: 23913553
  29. results show that Brachyury expression is enhanced during TGF-beta1-induced epithelial-mesenchymal transition in human cancer cell lines and that a positive feedback loop is established between Brachyury and TGF-beta1 in mesenchymal-like tumor cells PMID: 23783250
  30. Brachyury expression may attenuate cell cycle progression, enabling tumor cells to become less susceptible to chemotherapy and radiation in human carcinomas. PMID: 23788039
  31. The results of this study suggested that brachyury-negative chordomas are biologically distinct from brachyury-positive chordomas and that T/brachyury might be an appropriate molecular therapeutic target for chordoma. PMID: 23965741
  32. heterochromatin-specific nonhistone chromosomal protein HP-1 PMID: 23218904
  33. Our findings present clinical evidence for an important role of Brachyury in EMT in oral SCC, and suggest that Brachyury and EMT patterns are useful prognostic markers. PMID: 23076115
  34. Data show a combination of only five genes (-BCL6, T (BRACHYURY), c-MYC, MITF and BAF60C (SMARCD3) rapidly and efficiently convert postnatal chorion and decidual cells into chondrocytes. PMID: 22833560
  35. Functional significance of Brachyury in the developmental program of hematopoietic differentiation from embryonic stem cells. PMID: 22548442
  36. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. PMID: 22847733
  37. Propose the use of brachyury as an additional helpful immunohistochemical marker to resolve the differential diagnosis of hemangioblastoma and histologic mimics. PMID: 22446946
  38. Genom-wide association identifies the T gene as a novel asthma pharmacogenetic locus. PMID: 22538805
  39. Brachyury and related Tbx proteins interact with the Mixl1 homeodomain protein and negatively regulate Mixl1 transcriptional activity PMID: 22164283
  40. BRACHYURY may regulate NANOG in mesenchymal-like CRC cells to impose a 'plastic-state', allowing competence of cells to respond to signals prompting invasion or metastasis. PMID: 21365650
  41. Loss of p27(Kip)(1) causes an elongated/scatter cell-like phenotype involving up-regulation of Brachyury and Twist gene expression. PMID: 21478681
  42. BRA was necessary for and preceded CDX2 expression. PMID: 21816365
  43. DeltaNP63 is not expressed and is therefore rarely, if ever, a transcriptional regulator of brachyury in human osteosarcomas and chordomas. PMID: 22007675
  44. Brachyury expression predicts poor prognosis at early stages of colorectal cancer PMID: 21220197
  45. The tumor cells were diffusely positive for brachyury and cytokeratin 19 on immunohistochemistry, suggesting that the tumor was extra-axial soft tissue chordoma. PMID: 21397407
  46. This study confirms the specificity of brachyury for chordoma in the differential diagnostic distinction from the potential genitourinary mimics, germ cell tumors and metastatic clear cell renal cell carcinoma. PMID: 21102418
  47. brachyury expressed in chordoma tumor cells, but not in benign notochoral cell rests that were coexistent. PMID: 20855213
  48. findings show chromosomal aberrations resulting in gain of the T locus are common in sporadic chordomas and expression of this gene is critical for proliferation of chordoma cells in vitro PMID: 21171078
  49. Exclusive brachyury expression in more than 90% of chordomas indicates its value as a unique, specific marker. PMID: 20670140
  50. Human T and risk for neural tube defects. PMID: 11897834

Show More

Hide All

Involvement in disease
Neural tube defects (NTD); Chordoma (CHDM); Sacral agenesis with vertebral anomalies (SAVA)
Subcellular Location
Nucleus.
Tissue Specificity
Detected in testis, but not in other, normal tissues. Detected in lung tumors (at protein level).
Database Links

HGNC: 11515

OMIM: 182940

KEGG: hsa:6862

STRING: 9606.ENSP00000296946

UniGene: Hs.389457

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1